Technology
Health
Biotechnology

Opiant

$10.71
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.07 (-0.65%) Today
-$0.04 (-0.37%) After Hours

Why Robinhood?

You can buy or sell Opiant and other stocks, options, ETFs, and crypto commission-free!

About

Opiant Pharmaceuticals, Inc. engages in the development of pharmaceutical solutions for common addictions and related disorders. It focuses on developing treatment to reverse opioid overdoses, treatment for overweight and obese patients with binge eating disorder and treatment for patients with Bulimia Nervosa. Read More Its principal product Naloxone is a medicine which is available through injection can reverse the overdose of prescription and illicit opioids. Opiant Pharmaceuticals was founded on June 21, 2005 and is headquartered in Santa Monica, CA.

Employees
16
Headquarters
Santa Monica, California
Founded
2005
Market Cap
42.20M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
32.31K
High Today
$10.75
Low Today
$10.23
Open Price
$10.67
Volume
15.09K
52 Week High
$29.55
52 Week Low
$10.00

Collections

Technology
Health
Biotechnology
Pharmaceutical
Medical
2016 IPO
US
North America

News

Yahoo FinanceMay 13

OPNT: Encouraging Pharmacokinetic Data for OPNT003…

By David Bautz, PhD NASDAQ:OPNT READ THE FULL OPNT RESEARCH REPORT Financial Update On May 9, 2019, Opiant (OPNT) announced financial results for the first quarter of 2019. The company recorded a total of $5.4 million in revenue for the three months ending Mar. 31, 2019, which consisted of $3.7 million in royalty revenue from the sale of NARCAN® Nasal Spray, $1.6 million of grant and contract revenue, and $0.08 million from treatment investment revenue. This compares to royalty revenue of $1.6 m...

50
Seeking AlphaMay 13

Opiant Pharmaceuticals, Inc. CEO Roger Crystal on Q1 2019 Results - Earnings Call Transcript

Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Q1 2019 Earnings Conference Call May 9, 2019 4:30 PM ET Company Participants Brian Ritchie - IR, LifeSci Advisors Roger Crystal - CEO David O'Toole - CFO Conference Call Participants Brandon Folkes - Cantor Fitzgerald David Bautz - Zacks Investment Research Operator Greetings, and welcome to the Opiant Pharmaceuticals First Quarter 2019 Earnings Conference Call. [Operator Instructions] As a reminder, this conference is being recorded. It is now my pleasur...

14
Yahoo FinanceMay 9

Opiant Pharmaceuticals Reports First Quarter 2019 Financial Results and Provides Corporate Update

SANTA MONICA, Calif., May 09, 2019 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (OPNT), a specialty pharmaceutical company developing medicines for addictions and drug overdose, today reported financial results for the three months ended March 31, 2019, and provided a corporate update. “We continue to advance our addiction and drug overdose-focused pipeline, and are committed to validating the data in peer-reviewed journals,” said Roger Crystal, M.D., Chief Executive Officer of Opiant. “Cl...

30

Earnings

Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
Actual
Expected Aug 8, After Hours
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.